Combined Companies Offer Broad Portfolio of Formulation Technologies in US & EU. Adds Extensive Early-Phase Development & Analytical Services. See Details.
- Our Locations
Find a Catalent location near you.
Contact us today!
- Development Expertise
Premium Delivery, Faster to Market
Integrated Services
- Inhalation Dev and Supply
World-Class Expertise Developing &
Manufacturing Inhaled Products
- Dose Form Design
Faster Development, Better Patient
Acceptance and Compliance.
- Cold Chain Challenges?
Catalent Is A Leading Reverse
Distributor For Pharma Products.
- Late Stage Customization
Drive Greater Speed, Flexibility &
Efficiency to Your Supply Chain
- Our Locations
Siemens Digitalization & Sustainable Solutions Ensure Labs are Safe, Secure and Compliant. Life Science Solutions from Siemens: Leading the Way in Science. Learn More Today!
Suchergebnisse
Suchergebnisse:
Acquisition International Magazine’s M&A Award 2022 for Best Cell & Gene Therapy Acquisition 2022. Juniper Biologics Pte Ltd, a top science-led pharmaceutical company focused on researching, developing and commercializing novel therapies.
3. Juli 2018 · Juniper Pharmaceuticals, Inc.’s core businesses include Juniper Pharma Services, which provides high-end fee-for-service pharmaceutical development and clinical trials manufacturing to clients, and its contract with Merck KGaA to supply CRINONE® (progesterone gel) outside of the United States.
We are a science-led healthcare company focused on researching, developing & commercialising novel therapies. Headquartered in Singapore, we have commercial operations in China, Japan, Asia, Australia & New Zealand, Middle East & Africa. Our approach.
Pipeline - Juniper Biologics. Pipeline for continuous benefit to patients. We’re working to identify more unmet medical needs and focus our research where it is needed most.
3. Juli 2018 · About Juniper Pharmaceuticals. Juniper Pharmaceuticals, Inc.'s core businesses include its CRINONE ® (progesterone gel) franchise and Juniper Pharma Services, which provides high-end...
15. Aug. 2018 · Dive Brief: Catalent announced Tuesday that it completed its deal to acquire U.K.-based Juniper Pharmaceuticals for $11.50 per share, or a total value of $130 million. The acquisition will strengthen Catalent’s offerings in formulation development, bioavailability solutions, and clinical-scale oral dose manufacturing.
10. Juli 2018 · Catalent has agreed to acquire Juniper Pharmaceuticals, a Boston, Massachusetts-headquartered specialty pharmaceutical company with contract development and manufacturing services, including its Nottingham, UK-based Juniper Pharma Services Division, in a deal worth $133 million.
